Safety assessments
toxicity, DLTs
ADVERSE EVENTS, ADVERSE EVENT, ADVERSE EVENT
All patients who received at least two doses of NEO-201 were evaluable for safety and toxicity unless they were removed from study therapy for DLT. Safety evaluations were conducted at every treatment cycle, including determination of adverse events, DLTs during the dose-escalation stage, clinical laboratory measurements, vital signs, and physical examinations. Adverse events were assessed according to the NCI-Common Terminology Criteria for Adverse Events Version 5.0 and were monitored until 30 days after the last dose of study drug.